Literature DB >> 34856865

Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?

Gianluca Perego1, Antonio Ghidini2, Andrea Luciani3, Fausto Petrelli3.   

Abstract

Immunotherapeutic drugs and target therapies have represented an epochal change in treating cancer patients. They represent an attractive option in oncologists' armamentarium, particularly if we consider the optimal balance between efficacy and toxicity. As a step forward, immuno- and target-therapies have merged intending to improve efficacy: antibody-drug conjugates ensure the perfect combination. They allow the delivery of large amounts of drugs to the target with a limited 'off-target' effect and a low rate of adverse events. These aspects could make immunoconjugates palatable as the first choice for fragile patients, but solid evidence does not exist on the use of these drugs in this population type, especially older people.

Entities:  

Keywords:  Immunoconjugates; efficacy; immunotherapy; monoclonal antibody; older population; toxicity

Mesh：

Substances：

Year:  2021        PMID： 34856865      PMCID： PMC8903970          DOI： 10.1080/21645515.2021.1999711

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  33 in total

1.  Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Virginia F Borges; Cristiano Ferrario; Nathalie Aucoin; Carla Falkson; Qamar Khan; Ian Krop; Stephen Welch; Alison Conlin; Jorge Chaves; Philippe L Bedard; Marc Chamberlain; Todd Gray; Alex Vo; Erika Hamilton
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Authors:  Ian E Krop; Sung-Bae Kim; Antonio González-Martín; Patricia M LoRusso; Jean-Marc Ferrero; Melanie Smitt; Ron Yu; Abraham C F Leung; Hans Wildiers
Journal:  Lancet Oncol       Date:  2014-05-02       Impact factor: 41.316

3.  Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Authors:  Salvatore Siena; Maria Di Bartolomeo; Kanwal Raghav; Toshiki Masuishi; Fotios Loupakis; Hisato Kawakami; Kensei Yamaguchi; Tomohiro Nishina; Marwan Fakih; Elena Elez; Javier Rodriguez; Fortunato Ciardiello; Yoshito Komatsu; Taito Esaki; Ki Chung; Zev Wainberg; Andrea Sartore-Bianchi; Kapil Saxena; Eriko Yamamoto; Emarjola Bako; Yasuyuki Okuda; Javad Shahidi; Axel Grothey; Takayuki Yoshino
Journal:  Lancet Oncol       Date:  2021-05-04       Impact factor: 41.316

4.  Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Sara A Hurvitz; Luc Dirix; Judit Kocsis; Giulia V Bianchi; Janice Lu; Jeferson Vinholes; Ellie Guardino; Chunyan Song; Barbara Tong; Vivian Ng; Yu-Waye Chu; Edith A Perez
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

5.  Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Authors:  Denise A Yardley; Ian E Krop; Patricia M LoRusso; Musa Mayer; Brian Barnett; Bongin Yoo; Edith A Perez
Journal:  Cancer J       Date:  2015 Sep-Oct       Impact factor: 3.360

Review 6.  Antibody-drug conjugates for cancer therapy.

Authors:  Anish Thomas; Beverly A Teicher; Raffit Hassan
Journal:  Lancet Oncol       Date:  2016-06       Impact factor: 41.316

7.  Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.

Authors:  Jhanelle E Gray; Rebecca S Heist; Alexander N Starodub; D Ross Camidge; Ebenezer A Kio; Gregory A Masters; W Thomas Purcell; Michael J Guarino; Jamal Misleh; Charles J Schneider; Bryan J Schneider; Allyson Ocean; Tirrell Johnson; Leena Gandhi; Kevin Kalinsky; Ronald Scheff; Wells A Messersmith; Serengulam V Govindan; Pius P Maliakal; Boyd Mudenda; William A Wegener; Robert M Sharkey; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

8.  Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Authors:  Solange Peters; Rolf Stahel; Lukas Bubendorf; Philip Bonomi; Augusto Villegas; Dariusz M Kowalski; Christina S Baik; Dolores Isla; Javier De Castro Carpeno; Pilar Garrido; Achim Rittmeyer; Marcello Tiseo; Christoph Meyenberg; Sanne de Haas; Lisa H Lam; Michael W Lu; Thomas E Stinchcombe
Journal:  Clin Cancer Res       Date:  2018-09-11       Impact factor: 12.531

9.  Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

Authors:  Jame Abraham; Albert J Montero; Rachel C Jankowitz; Mohamad Adham Salkeni; Jan H Beumer; Brian F Kiesel; Fanny Piette; Laura M Adamson; Rebecca J Nagy; Richard B Lanman; Jeff Sperinde; Weidong Huang; Carmen J Allegra; Ashok Srinivasan; Ying Wang; Katherine L Pogue-Geile; Peter C Lucas; Samuel A Jacobs
Journal:  J Clin Oncol       Date:  2019-08-23       Impact factor: 44.544

10.  Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program.

Authors:  Supriya G Mohile; Ronald M Epstein; Arti Hurria; Charles E Heckler; Beverly Canin; Eva Culakova; Paul Duberstein; Nikesha Gilmore; Huiwen Xu; Sandy Plumb; Megan Wells; Lisa M Lowenstein; Marie A Flannery; Michelle Janelsins; Allison Magnuson; Kah Poh Loh; Amber S Kleckner; Karen M Mustian; Judith O Hopkins; Jane Jijun Liu; Jodi Geer; Rita Gorawara-Bhat; Gary R Morrow; William Dale
Journal:  JAMA Oncol       Date:  2020-02-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.